

Supplementary Table S1. Grade > 1 Toxicity

| Neoadjuvant Phase | | | | | | |
|--------------------------|--|-----------------------|-----------------------|--|-----------------------|-----------------------|
| Adverse Event | FEC Chemotherapy (total, n = 63) | | | | | |
| | <u>Grade 2</u> | | <u>Grade 3</u> | | <u>Grade 4</u> | |
| | n (%) | | n (%) | | n (%) | |
| Alopecia | 29 (46) | | 0 | | 0 | |
| Neutropenia | 17 (27) | | 14 (22) | | 7 (11) | |
| Leukopenia | 13 (21) | | 7 (11) | | 1 (2) | |
| Nausea | 9 (14) | | 0 | | 0 | |
| Fatigue | 8 (13) | | 0 | | 0 | |
| Erythema | 1 (2) | | 0 | | 0 | |
| Fever | 1 (2) | | 0 | | 0 | |
| Vomiting | 1 (2) | | 0 | | 0 | |
| ALT increased | 1 (2) | | 0 | | 0 | |
| Anemia | 1 (2) | | 0 | | 0 | |
| Constipation | 1 (2) | | 0 | | 0 | |
| Adverse Event | Arm A (CIT* + IV Trastuzumab) (total, n = 31) | | | Arm B (CIT* + SC Trastuzumab) (total, n = 32) | | |
| | <u>Grade 2</u> | <u>Grade 3</u> | <u>Grade 4</u> | <u>Grade 2</u> | <u>Grade 3</u> | <u>Grade 4</u> |
| | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
| Alopecia | 7 (23) | 0 | 0 | 6 (19) | 0 | 0 |

| | | | | | | |
|---------------------------------|---|-----------------------|-----------------------|--|-----------------------|-----------------------|
| Neutropenia | 1 (3) | 6 (19) | 3 (10) | 3 (9) | 6 (19) | 3 (9) |
| Leukopenia | 2 (6) | 3 (10) | 1 (3) | 4 (12.5) | 2 (6) | 0 |
| Diarrhea | 6 (19) | 1 (3) | 0 | 4 (12.5) | 1 (3) | 0 |
| Mucosal inflammation | 4 (13) | 1 (3) | 0 | 5 (16) | 0 | 0 |
| Fatigue | 3 (10) | 2 (6) | 0 | 3 (9) | 0 | 0 |
| Anemia | 2 (6) | 0 | 0 | 0 | 0 | 0 |
| Erythema | 1 (3) | 0 | 0 | 2 (6) | 1 (3) | 0 |
| Peripheral neuropathy (sensory) | 1 (3) | 0 | 0 | 2 (6) | 1 (3) | 0 |
| Vomiting | 0 | 0 | 0 | 2 (6) | 0 | 0 |
| ALT increased | 0 | 0 | 0 | 2 (6) | 0 | 0 |
| Nausea | 0 | 0 | 0 | 3 (9) | 0 | 0 |
| Adjuvant Phase | | | | | | |
| | Arm A (IV Trastuzumab) (total, n = 31) | | | Arm B (SC Trastuzumab) total, n = 32) | | |
| | <u>Grade 2</u> | <u>Grade 3</u> | <u>Grade 4</u> | <u>Grade 2</u> | <u>Grade 3</u> | <u>Grade 4</u> |
| Adverse Event | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
| Fatigue | 2 (6) | 0 | 0 | 0 | 0 | 0 |
| Peripheral neuropathy (sensory) | 1 (3) | 1 (3) | | 1 (3) | 2 (6) | |
| Alopecia | 1 (3) | | | 1 (3) | | |
| Neutropenia | 0 | 0 | 0 | 0 | 1 (3) | 0 |
| Anemia | 1 (3) | 0 | 0 | 0 | 0 | 0 |
| Erythema | 1 (3) | 0 | 0 | 0 | 1 (3) | 0 |

| | | | | | | |
|---------------------------------|-------|-------|---|-------|-------|---|
| Mucosal inflammation | 1 (3) | 0 | 0 | 0 | 0 | 0 |
| Peripheral neuropathy (sensory) | 1 (3) | 1 (3) | | 1 (3) | 2 (6) | 0 |

Abbreviations: FEC, 5-fluorouracil, epirubicin, cyclophosphamide; n, number; %, percentage; ALT, alanine aminotransferase CIT, chemoimmunotherapy.

*Docetaxel + Pertuzumab